Anaemia is very common among patients with moderate or severe chronic kidney disease; and several treatments are available including iron supplementation, blood transfusions and synthetic derivatives of erythropoietin. In a Cochrane Review published in December 2014, Suetonia Palmer from Christchurch in New Zealand together with her colleagues, brought together the studies that have tested a range of erythropoietin drugs and she tells us what they found in this podcast.